RESEARCH ARTICLE
Screening HIV-Infected Patients with Low CD4 Counts for Cryptococcal Antigenemia prior to Initiation of Antiretroviral Therapy: Cost Effectiveness of Alternative Screening Strategies in South Africa a11111
OPEN ACCESS Citation: Larson BA, Rockers PC, Bonawitz R, Sriruttan C, Glencross DK, Cassim N, et al. (2016) Screening HIV-Infected Patients with Low CD4 Counts for Cryptococcal Antigenemia prior to Initiation of Antiretroviral Therapy: Cost Effectiveness of Alternative Screening Strategies in South Africa. PLoS ONE 11(7): e0158986. doi:10.1371/journal. pone.0158986 Editor: Sarah L Pett, Faculty of Medicine, AUSTRALIA Received: April 22, 2016 Accepted: June 26, 2016 Published: July 8, 2016 Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication. Data Availability Statement: All relevant data are within the paper and its Supporting Information files. Funding: Boston University School of Public received a grant from the CDC Foundation, which provided support to BU and HE2RO related authors for completing this analysis. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Bruce A. Larson1*, Peter C. Rockers1, Rachael Bonawitz1,7, Charlotte Sriruttan2, Deborah K. Glencross3,4, Naseem Cassim3,4, Lindi M. Coetzee3,4, Gregory S. Greene6, Tom M. Chiller6, Snigdha Vallabhaneni6, Lawrence Long4,5, Craig van Rensburg4,5, Nelesh P. Govender2,4 1 Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, United States of America, 2 National Institute for Communicable Diseases – Centre for Opportunistic, Tropical and Hospital Infections, Johannesburg, South Africa, 3 National Health Laboratory Service, Johannesburg, South Africa, 4 Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 5 Health Economics and Epidemiology Office, Wits Health Consortium, Johannesburg, South Africa, 6 Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America, 7 Department of Pediatrics, Boston University School of Medicine, Boston, Massachusetts, United States of America * [email protected]
Abstract Background In 2015 South Africa established a national cryptococcal antigenemia (CrAg) screening policy targeted at HIV-infected patients with CD4+ T-lymphocyte (CD4) counts
Screening HIV-Infected Patients with Low CD4 Counts for Cryptococcal Antigenemia prior to Initiation of Antiretroviral Therapy: Cost Effectiveness of Alternative Screening Strategies in South Africa a11111
OPEN ACCESS Citation: Larson BA, Rockers PC, Bonawitz R, Sriruttan C, Glencross DK, Cassim N, et al. (2016) Screening HIV-Infected Patients with Low CD4 Counts for Cryptococcal Antigenemia prior to Initiation of Antiretroviral Therapy: Cost Effectiveness of Alternative Screening Strategies in South Africa. PLoS ONE 11(7): e0158986. doi:10.1371/journal. pone.0158986 Editor: Sarah L Pett, Faculty of Medicine, AUSTRALIA Received: April 22, 2016 Accepted: June 26, 2016 Published: July 8, 2016 Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication. Data Availability Statement: All relevant data are within the paper and its Supporting Information files. Funding: Boston University School of Public received a grant from the CDC Foundation, which provided support to BU and HE2RO related authors for completing this analysis. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Bruce A. Larson1*, Peter C. Rockers1, Rachael Bonawitz1,7, Charlotte Sriruttan2, Deborah K. Glencross3,4, Naseem Cassim3,4, Lindi M. Coetzee3,4, Gregory S. Greene6, Tom M. Chiller6, Snigdha Vallabhaneni6, Lawrence Long4,5, Craig van Rensburg4,5, Nelesh P. Govender2,4 1 Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, United States of America, 2 National Institute for Communicable Diseases – Centre for Opportunistic, Tropical and Hospital Infections, Johannesburg, South Africa, 3 National Health Laboratory Service, Johannesburg, South Africa, 4 Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 5 Health Economics and Epidemiology Office, Wits Health Consortium, Johannesburg, South Africa, 6 Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America, 7 Department of Pediatrics, Boston University School of Medicine, Boston, Massachusetts, United States of America * [email protected]
Abstract Background In 2015 South Africa established a national cryptococcal antigenemia (CrAg) screening policy targeted at HIV-infected patients with CD4+ T-lymphocyte (CD4) counts
